On June 12, 2025, Piper Sandler analyst David Amsellem reiterated his rating and price target for Biogen (BIIB, Financial). The analyst maintained a 'Neutral' rating on the stock, consistent with his prior evaluation.
The price target for Biogen (BIIB, Financial) remains unchanged at $115.00 USD. This indicates that Piper Sandler continues to see Biogen's stock value stable at its current level.
Investors closely monitoring Biogen (BIIB, Financial) can note that there has been no change in the analyst’s outlook or price projections for the company, reflecting a steady perspective from Piper Sandler regarding the biotech giant.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 29 analysts, the average target price for Biogen Inc (BIIB, Financial) is $169.94 with a high estimate of $260.00 and a low estimate of $115.00. The average target implies an upside of 27.83% from the current price of $132.94. More detailed estimate data can be found on the Biogen Inc (BIIB) Forecast page.
Based on the consensus recommendation from 37 brokerage firms, Biogen Inc's (BIIB, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Biogen Inc (BIIB, Financial) in one year is $211.27, suggesting a upside of 58.92% from the current price of $132.94. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Biogen Inc (BIIB) Summary page.
